(Q50582782)

16 March 2018

title

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance (English)

1 reference

16 March 2018

1 reference

J Tilman Gerlach

1

1 reference

16 March 2018

Helmut M Diepolder

2

1 reference

16 March 2018

Reinhart Zachoval

3

1 reference

16 March 2018

Norbert H Gruener

4

1 reference

16 March 2018

Maria-Christina Jung

5

1 reference

16 March 2018

Axel Ulsenheimer

6

1 reference

16 March 2018

Winfried W Schraut

7

1 reference

16 March 2018

C Albrecht Schirren

8

1 reference

16 March 2018

M Waechtler

9

1 reference

16 March 2018

M Backmund

10

1 reference

16 March 2018

Gerd R Pape

11

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 July 2003

1 reference

16 March 2018

published in

Gastroenterology

1 reference

16 March 2018

volume

125

1 reference

16 March 2018

issue

1

1 reference

16 March 2018

page(s)

80-88

1 reference

16 March 2018

The Declining Risk of Post-Transfusion Hepatitis C Virus Infection

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Epidemiology of hepatitis C in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Resolution of acute hepatitis C after therapy with natural beta interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Methods for the differentiation of microorganisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

HCV RNA in blood donors with isolated reactivities by third-generation RIBA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Peginterferon alfa-2a in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Determinants of viral clearance and persistence during acute hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Interferon as treatment for acute hepatitis C. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Treatment of acute hepatitis C with interferon alfa-2b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Therapy for acute hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

Acute hepatitis C: to treat or not to treat?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900668-1

10.1016/S0016-5085(03)00668-1

7 January 2021

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018